GlassScriptPhysician profile
John Patrick L Tejada
NPI 1801104559
$16,074.42
in general payments reported to CMS, 2019-2025
37 companies · $7,410 in 2025
The $7,410 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,171 · 2021: $1,681 · 2022: $1,682 · 2023: $1,500 · 2024: $1,427 · 2025: $7,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,517 · Food and Beverage: $4,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,517.38 |
| Food and Beverage | $4,819.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,594.54 | 2024-2025 | |
| Glaxosmithkline, LLC. | $1,818.29 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,330.15 | 2019-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $1,158.85 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Genzyme Corporation | $909.76 | 2019-2025 | |
| United Therapeutics Corporation | $876.27 | 2019-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $846.27 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Insmed, INC. | $655.41 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $442.55 | 2019-2024 | Yupelri |
| Gilead Sciences, INC. | $376.83 | 2021-2024 | Veklury |
| Regeneron Healthcare Solutions, INC. | $246.47 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $237.85 | 2019-2025 | Winrevair |
| Verona Pharma, INC. | $198.49 | 2025 | Ohtuvayre |
| Inari Medical, INC. | $185.42 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $155.70 | 2021-2025 | Tezspire |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $127.94 | 2019-2025 | |
| Baxter Healthcare | $108.61 | 2023-2024 | Hillrom - Life 2000 Ventilation System |
| Takeda Pharmaceuticals U.S.A., INC. | $106.46 | 2020-2024 | Glassia |
| Genentech USA, INC. | $85.73 | 2019-2024 | Xolair |
| Electromed, INC. | $79.49 | 2023 | Smartvest |
| Ani Pharmaceuticals, INC. | $65.10 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $62.31 | 2019 | |
| Advanced Respiratory, INC | $54.79 | 2020-2021 | |
| Viatris Specialty LLC | $46.76 | 2025 | Yupelri |
| Harmony Biosciences LLC | $44.60 | 2021-2024 | |
| Grifols USA, LLC | $43.01 | 2020-2025 | Xembify |
| Resmed Corp | $32.80 | 2021 | |
| Liquidia Technologies, INC. | $25.41 | 2025 | Yutrepia |
| Fisher & Paykel Healthcare INC | $23.71 | 2022 | |
| Portola Pharmaceuticals, LLC | $22.51 | 2020 | |
| Shire North American Group INC | $21.83 | 2019 | |
| Pfizer INC. | $17.19 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.87 | 2019 | |
| Medtronic, INC. | $15.38 | 2025 | Illumisite |
| Csl Behring | $14.64 | 2020 | |
| Circassia INC. | $14.48 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Patrick Tejada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.